In 2023, the FDA banned 19 peptides from compounding pharmacies. No specific safety incident. No clear signal. Just a regulatory decision that pushed millions of patients toward gray market suppliers and overseas An Evaluation Benchmark for Adverse Drug Event Prediction from Clinical Trial Results Scientific Data Frontiers Post marketing safety of anakinra and canakinumab: a real world pharmacovigilance study based on FDA adverse event reporting system Population Scale Identification of Differential Adverse Events Before and During a Pandemic Zitnik Lab